One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Levofloxacin Market

[ 英語タイトル ] Levofloxacin Market

Product Code : MDHC0089202
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 122
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Aden Healthcare
- Allenge India Pharma
- Alna Biotech Private Limited
- Bestochem
- Dr. Reddy's Laboratories Ltd
- Glenmark Pharmaceuticals
- Lupin Limited
- Zydus Cadila

[Report Description]

The global levofloxacin market was anticipated to record a CAGR of nearly 5.1% during the forecast period. The rise in the cases of bacterial infectious diseases, along with the growing number of baby boomers, is the main factor driving the growth of this market. As per the World Health Organization, pneumonia accounts for 15% of all deaths of children under 5 years old, killing 8,08,694 children in 2017. High burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens have been augmenting the market.

Increasing efforts undertaken by major companies for the development of advanced products will also support market growth. Involvement of international organizations serves as a catalyst in the levofloxacin market. Funding bodies, such as BARDA, are supporting biotech companies with financial support to complete early stage development of their novel therapies for infectious diseases. Furthermore, supportive government legislation, such as the Generating Antibiotics Incentives Now (GAIN) Act, is anticipated to bolster the approval process. The legislation aims to promote the development of therapies for growing burden and severity of antibiotic-resistant infections. These factors are also supporting the development and uptake of levofloxacin antibiotics.

However, lack of awareness associated with infectious disease may hamper business growth in the future.

Key Market Trends

Pneumonia Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period

- Pneumonia, by application segment, is expected to dominate the global levofloxacin market through the forecast period. Increasing incidence of pneumococcal disease is a high impact rendering driver. Over the years, there has been a significant upsurge in the number of community-acquired and ventilator-associated bacterial pneumonia.
- These infections pose treatment challenges for physicians due to high resistance to current treatment alternatives, thereby imposing a high-cost burden. According to the World Health Organization, The cost of antibiotic treatment for all children with pneumonia is estimated at around USD 109 million per year. The aforementioned factors are driving the demand for the product.

North America Dominates the Market and is Expected to Continue the Same during the Forecast Period

North America is leading, owing to the presence of major market players. Furthermore, factors such as the increasing prevalence of chronic diseases, treatment costs, technological advancements, and product launches are expected to drive regional growth. Also, various government initiatives aimed at the prevention and treatment of pneumonia are responsible for creating a positive impact across North America. For instance, the Integrated Global Action Plan for Pneumonia and Diarrhea by UNICEF and WHO is aimed at minimizing preventable child deaths due to diarrhea and pneumonia. This initiative is focused on interventions and services that raise awareness and increase access to treatment and preventive measures, flourishing the regional growth for the levofloxacin market.

Asia-Pacific is expected to show exponential growth throughout the forecast period. This growth can be attributed to the increased prevalence of pneumococcal disease, unmet patient needs, increased cases of antimicrobial resistance, and rise in disorders leading to weakened immune system, thereby, contributing to the growth of the region.

Competitive Landscape

The market for levofloxacin is consolidated and consists of the global as well as local players. The consolidated environment is marked by key players extensively deploying sustainability strategies. Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd, and Zydus Cadila are some of the most notable companies. These companies are involved in new product development initiatives, mergers and acquisitions, and geographical expansion.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Number of Baby Boomers
4.2.2 Growing Incidence of Bacterial Infections
4.2.3 Supportive Government Legislation
4.3 Market Restraints
4.3.1 Lack of Awaeness Associated with Infectious Disease
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Application
5.1.1 Pneumonia
5.1.2 Skin Infection
5.1.3 Kidney Infection
5.1.4 Bladder Infection
5.1.5 Other Applications
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Aden Healthcare
6.1.2 Allenge India Pharma
6.1.3 Alna Biotech Private Limited
6.1.4 Bestochem
6.1.6 Dr. Reddy's Laboratories Ltd
6.1.7 Glenmark Pharmaceuticals
6.1.8 Lupin Limited
6.1.10 Zydus Cadila




Recommended reports